Graham Pawelec Biosketch
Graham Pawelec received an MA in Natural Sciences in 1978 and a PhD in Transplantation Immunology in 1982 from the University of Cambridge, UK, and the Dr. habil and Venia Legendi from the University of Tübingen, Germany, where he became Professor of Experimental Immunology in 1997. He is affiliated to the Center for Medical Research, University of Tübingen Medical School (Section for Transplantation Immunology, 2nd Department of Internal Medicine).
His research interests are now centered on alterations to immunity, especially T cell-mediated immunity, in ageing, age-associated diseases and cancer in man and the influence these have on the outcome of vaccination. He is currently focusing on mechanisms of human immunosenescence and the initially unexpected and surprising discovery of the impact of infection with the common herpesvirus Cytomegalovirus on immunity and mortality in the elderly. The impact of polypathogenicity (including multiple infections, cancer, Alzheimer´s, autoimmunity) as well as stress (psychological, nutritional) on immune signatures reflecting individual immune status is of particular interest in the clinical context.
He is a Visiting Professor, Nottingham Trent University, UK, and Honorary Professor at Manchester University, UK. He is Co-Editor-in Chief of Cancer Immunology Immunotherapy, Deputy Editor of Immunity & Ageing, and the Journal of Translational Medicine, Associate Editor of Mechanisms of Ageing & Development, and on the Editorial Boards of J. Gerontology Series A, Age, Experimental Gerontology and Biogerontology. He has authored >150 peer-reviewed original articles from a total of >300 publications, has edited 3 books and co-edited several others. He has coordinated three European Union collaborative programs on immunosenescence (EUCAMBIS, ImAginE and T-CIA) and two on cancer vaccine research (EUCAPS, ESTDAB). He was an EU 5th Framework Program Expert Advisory Panel Member for Ageing and Public Health, 1997, and 7th FP Expert Consultant for the ‘Road map for the future of ageing research in Europe’, 2007 as well as the 7th FP “WhyWeAge” 2010 consulting exercise to make recommendations on the priorities for European research on ageing over the next decade.
He was a member of the Sanofi-Pasteur-MSD and Sanofi-Aventis Advisory Boards on Immunosenescence and Vaccination, and of the WHO Initiative for Vaccine Research Advisory Board on the Impact of Ageing on Vaccination.